mirtazapine has been researched along with Epidermolysis Bullosa Dystrophica in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Epidermolysis Bullosa Dystrophica: Form of epidermolysis bullosa characterized by atrophy of blistered areas, severe scarring, and nail changes. It is most often present at birth or in early infancy and occurs in both autosomal dominant and recessive forms. All forms of dystrophic epidermolysis bullosa result from mutations in COLLAGEN TYPE VII, a major component fibrils of BASEMENT MEMBRANE and EPIDERMIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, S | 1 |
| Azevedo, A | 1 |
| Velho, GC | 1 |
| Sanches, M | 1 |
| Selores, M | 1 |
1 other study available for mirtazapine and Epidermolysis Bullosa Dystrophica
| Article | Year |
|---|---|
Epidermolysis Bullosa Pruriginosa successfully treated with concomitant topical and systemic agents.
Topics: Administration, Topical; Amitriptyline; Analgesics; Drug Therapy, Combination; Epidermolysis Bullosa | 2020 |